Edesa Biotech RPE
What is the RPE of Edesa Biotech?
The RPE of Edesa Biotech, Inc. is $0.00
What is the definition of RPE?
Revenue per employee (RPE) is revenue divided by the number of employees of an organization.
= net income / number of employees
RPE of companies in the Health Care sector on NASDAQ compared to Edesa Biotech
What does Edesa Biotech do?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Companies with rpe similar to Edesa Biotech
- Imperial Pacific International has RPE of -HKD$428.57
- Indosolar has RPE of -₨115.24
- Bluejay Mining Plc has RPE of -£95.27
- Small Pharma Inc has RPE of -CAD$89.38
- Treasury Metals has RPE of -$82.14
- Treasury Metals has RPE of -CAD$4.56
- Edesa Biotech has RPE of $0.00
- medical columbus AG has RPE of €0.45
- Nyrstar NV has RPE of €2.96
- Talon Metals has RPE of CAD$10.55
- Highfield Resources has RPE of AUD$12.94
- Venus Metals has RPE of AUD$15.15
- Buderim has RPE of AUD$54.64